CORRECTION: Zealand announces advance by Sanofi of LixiLan, the single
injection Lyxumia(r)/Lantus(r) combination product, towards Phase III
development and a related milestone payment
*The first LixiLan Phase III study protocol has now been approved,
triggering a USD 15 million payment to Zealand from Sanofi
*This milestone is in line with recently updated plans by Sanofi to start
Phase III development in Q1 2014
COPENHAGEN, Jan. 15, 2014 (GLOBE NEWSWIRE) -- Zealand Pharma A/S
(Copenhagen:ZEAL) ("Zealand") announces that under its license agreement with
Sanofi (EURONEXT:SAN) (NYSE: SNY) covering Lyxumia^(r) (lixisenatide) and any
combination product including lixisenatide, a milestone has been achieved in
the advance of LixiLan, the once-daily single injection Lantus^(r) (basal
insulin) / Lyxumia^(r) (lixisenatide) combination product, towards start of
Phase III development in the 1^st quarter of 2014. The milestone relates to
the approval of the first Phase III study protocol for LixiLan by a Health
Authority, triggering a USD 15 million payment to Zealand.
Lixisenatide is a once-daily prandial GLP-1 receptor agonist invented by
Zealand for the treatment of Type 2 diabetes. Worldwide development and
commercial rights to the product are exclusively licensed to Sanofi.
The announced first LixiLan Phase III study protocol approval follows an
update provided by Sanofi yesterday at the Annual J.P. Morgan Healthcare
Conference, held in San Francisco, on the status of Lyxumia^(r) and LixiLan.
As part of the update, Sanofi confirmed plans to start Phase III development
of LixiLan in the 1^st quarter of 2014, narrowing its earlier guidance of an
expected start in H1 2014.
Further to this, in their presentation, Sanofi also confirmed that Lyxumia^(r)
is being introduced progressively in a larger number of countries as a new
once-daily prandial GLP-1 agonist therapy for patients with Type 2 diabetes.
In addition to its pronounced effect on lowering meal related glucose
(post-prandial glucose, PPG), Lyxumia^(r) has a beneficial effect on body
weight and is associated with a limited risk of hypoglycemia. This profile
makes Lyxumia^(r) particularly well suited for use as add-on therapy to basal
insulin, including Lantus^(r).
Welcoming the announced milestone of LixiLan Phase III advance and the update
from Sanofi, David Solomon, Chief Executive Officer of Zealand Pharma,
said:"We are very pleased to be able to share this important and confirmatory
milestone of the first LixiLan Phase III protocol approval. This news is fully
in line with Sanofi's expectations to start Phase III development in the 1st
quarter of 2014. Zealand believes that the combination of Lyxumia^(r) with
Lantus^(r), Sanofi's blockbuster product and the worldwide leading basal
insulin, into one single device has an exciting potential, in our view also
adding to the validation of the therapeutic relevance of Lyxumia^(r), the
first Zealand invented product on the market."
The milestone payment of USD 15 million from Sanofi will positively impact on
Zealand's financial results for 2014. Zealand will provide its financial
outlook for 2014 in connection with the issuance of the company's Full Year
announcement and Annual Report for 2014 on 20 March 2014.
Under the license agreement with Sanofi, covering lixisenatide (Lyxumia^(r))
and any combination products including lixisenatide, Zealand is eligible to up
to USD 160 million in remaining milestones. Further, Zealand will receive
tiered low double-digit percentage royalties on Sanofi's global sales of
Lyxumia^(r) and fixed low double-digit percentage royalties on global full net
sales of the Lyxumia^(r)/Lantus^(r) combination product.
For further information, please contact:
David H. Solomon, President and Chief Executive Officer
Tel: +45 2220 6300
Hanne Leth Hillman, Vice President and Head of IR & Corporate Communications
Tel: +45 5060 3689, email: email@example.com
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) ("Zealand") is a
biotechnology company based in Copenhagen, Denmark. Zealand specializes in the
discovery, optimization and development of novel peptide drugs and has a broad
and mature pipeline of drug candidates identified through its own drug
discovery activities. The company's focus lies in the field of
cardio-metabolic diseases, diabetes and obesity in particular, and its lead
drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is
licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide
(marketed by Sanofi as Lyxumia^(r)) is approved in several countries,
including Europe and Japan, and under regulatory review in a number of other
countries globally. In the U.S., an NDA is planned to be submitted in 2015,
after completion of the ELIXA Cardiovascular outcome study.
Zealand has a partnering strategy for the development and commercialization of
its products and in addition to the license agreement with Sanofi in Type 2
diabetes, the company has partnerships with Boehringer Ingelheim in
diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in
chemotherapy induced diarrhea and AbbVie in acute kidney injury.
For further information: www.zealandpharma.com
Press spacebar to pause and continue. Press esc to stop.